GlassScriptPhysician profile
Joseph A Hooper
NPI 1437190444
$11,728.17
in general payments reported to CMS, 2019-2025
55 companies · $1,402 in 2025
The $1,402 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $864 · 2020: $1,186 · 2021: $2,123 · 2022: $2,222 · 2023: $2,232 · 2024: $1,700 · 2025: $1,402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,321 · Entertainment: $13.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,320.60 |
| Entertainment | $13.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,760.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,022.07 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $742.75 | 2019-2025 | Repatha, Otezla, Otezla |
| Janssen Pharmaceuticals, INC | $674.23 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $657.60 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $616.57 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $616.24 | 2019-2025 | Jardiance |
| Abbvie INC. | $600.87 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $600.39 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $549.05 | 2021-2025 | |
| Abbott Laboratories | $423.26 | 2021-2025 | Freestyle Libre 3, Mitraclip |
| Astellas Pharma US INC | $350.46 | 2019-2025 | Veozah, Myrbetriq |
| Otsuka America Pharmaceutical, INC. | $190.74 | 2022-2025 | Rexulti |
| Dexcom, INC. | $163.51 | 2021-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $154.88 | 2019-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Hooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.